A curcumin derivative J147 ameliorates diabetic peripheral neuropathy in streptozotocin (STZ)-induced DPN rat models through negative regulation AMPK on TRPA1 1
8-Experimental SurgeryActa Cir Bras. 2018;33(6):533-541
AbstractPurpose: To investigate the specific molecular mechanisms and effects of curcumin derivative J147 on diabetic peripheral neuropathy (DPN). Methods: We constructed streptozotocin (STZ)-induced DPN rat models to detected mechanical withdrawal threshold (MWT) in vivo using Von Frey filaments. In vitro, we measured cell viability and apoptosis, adenosine 5'-monophosphate-activated protein kinase (AMPK) and transient receptor potential A1 (TRPA1) expression using MTT, flow cytometry, qRT-PCR and western blot. Then, TRPA1 expression level and calcium reaction level were assessed in agonist AICAR treated RSC96cells.
Results:The results showed that J147reduced MWT in vivo, increased the mRNA and protein level of AMPK, reduced TRPA1 expression and calcium reaction level in AITCR treated RSC96 cells, and had no obvious effect on cell viability and apoptosis. 18 reports that J147 improves the depression-like behavior in mouse models caused by chronic stress, and its mechanism may involve the regulation of cAMP/pCREB/ BDNF pathway.Due to curcumin can relieve diabetic peripheral neuropathic pain 14 , we aimed to investigate the specific molecular mechanisms and effects of J147 on DPN through the establishment of DPN rat models, cell viability and apoptosis assay in this study.
■ Methods
DPN rat modelsEthical Guidelines were approved by the Ethical Committee of Shanxi University of Traditional Chinese Medicine.The 30 adult male SPF rats (weighing 200 ± 20g) were obtained from Institute of Laboratory Animal Science, Chinese Academy of Medical Science (Beijing, China). They were housed in stainless steel squirrel cages with food and water available ad libitum. The breeding room was kept at 20°C, 70% humidity and 12 h of light.SPF rats were weighed after fasting for 12 h, and streptozotocin(STZ) solution (Solarbio, Beijing, China) was injected intraperitoneally at 50 mg/kg weight. After 4 h of injection, the rats resumed their diet
■ IntroductionDiabetic peripheral neuropathy (DPN) is one of the major disability factors and the most common chronic neurological complications in diabetes 1 . The clinical manifestations of this disease are distal symmetric pain with paresthesia, like numbness, ant walking, insect crawling, fever, electric shock, and motor neurological disorders 2,3 .Further, severe DPN patients may develop lower extremity arthropathy and ulcers 2 . In addition, there will be DPN in 30-50% diabetic patients by 2025 according to the prediction from WHO 4 . Therefore, in order to ameliorate the patient's clinical symptoms and control the development of DPN, the comprehensive treatments are used, such as control of blood glucose, oral Duloxetine and Pregabalin, interventional therapy and surgical treatment [5][6][7][8] . Regardless, the exact pathogenesis of DPN is not fully understood until now. ...